Citrus IntegroPectin: A Family of Bioconjugates With Large Therapeutic Potential

Abstract Citrus IntegroPectin is a family of bioconjugates sourced from different citrus fruits first isolated in 2019 via hydrodynamic cavitation of industrial citrus processing biowaste conducted in water only. Having a low methoxyl homogalacturonan backbone, these new pectins are enriched in citrus flavonoids, terpenes, and RG‐I rhamnogalacturonan regions. Investigating lemon, grapefruit, orange, red orange, and mandarin IntegroPectin in numerous in vitro and in vivo studies unveiled their multitarget biological activity, including antioxidant, anti‐inflammatory, cardioprotective, anti‐apoptotic, immunomodulatory, neuroprotective, mitoprotective, antimicrobial, and anticancer properties. This review summarizes research achievements in the first five years following the discovery of IntegroPectin. A critical perspective toward production and practical uptake of this new family of bioconjugates for the treatment and prevention of numerous ailments concludes this account.